Vivos Therapeutics Stock News

Vivos’ Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea Vivos’ Continuous Clinical Improvement Program Yields Promisi

Here are three penny stocks you should add to your watchlist The post These 3 Penny Stocks Exploded Today, Here’s Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

Here are three penny stocks you should add to your watchlist The post These 3 Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 35% during intraday trading today. This is why it happened.

Zogenix ZGNX +68%. Vivos Therapeutics VVOS +33%. Cardiff Oncology CRDF -24%. Yumanity Therapeutics YMTX -17%.

Nano-cap med-tech firm, Vivos Therapeutics <> is trading higher after announcing a sharp increase in the total number of SleepImage Home Sleep Apnea Tests ((HST)) given across

Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information |

Vivos Also Announces Improved Pricing Agreement With SleepImage

Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test HIGHLANDS RANCH, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . ("Vivos" or "the Company") (NASDAQ: VVOS ), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST). In particular, for the three-months ended December 31, 2021, versus the three-months ended December 31, 2020, Vivos reported: an 18 times increase in the total number of HSTs given across the network of Vivos trained dentists (known as Vivos Integrated Practices or VIPs); a 5.7 times increase in the number of VIPs administering HSTs; and a 3 times increase in the average number of HSTs being administered per VIP.

Vivos Therapeutics Inc (NASDAQ:VVOS) announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST). In particular, for the quarter ended December 31, 2021

Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information |

Vivos Therapeutics Inc (VVOS) shares closed today at 1.1% above its 52 week low of $1.85, giving the company a market cap of $43M. The stock is currently down 16.9% year-to-date, down 75.2% over the past 12 months, and down 79.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 1.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1498.8% The company's stock price performance over the past 12 months lags the peer average by -1127.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Vivos Therapeutics Inc (VVOS) shares closed today at 1.1% above its 52 week low of $1.85, giving the company a market cap of $43M. The stock is currently down 16.9% year-to-date, down 75.2% over the past 12 months, and down 79.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 0.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1498.8% The company's stock price performance over the past 12 months lags the peer average by -1127.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Vivos Therapeutics Inc (VVOS) shares closed today at 1.1% above its 52 week low of $1.85, giving the company a market cap of $43M. The stock is currently down 16.9% year-to-date, down 76.6% over the past 12 months, and down 79.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 0.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.0% lower than its 5-day moving average, 18.7% lower than its 20-day moving average, and 43.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1498.8% The company's stock price performance over the past 12 months lags the peer average by -887.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Vivos Therapeutics Inc (VVOS) shares closed 2.8% lower than its previous 52 week low, giving the company a market cap of $52M. The stock is currently up 0.4% year-to-date, down 62.4% over the past 12 months, and down 74.9% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 61.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -67.6% The company's stock price performance over the past 12 months lags the peer average by -554.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.